(NASDAQ: ALEC) Alector's forecast annual revenue growth rate of 20.95% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.37%, and while it is forecast to beat the US market's average forecast revenue growth rate of 14.15%.
Alector's revenue in 2026 is $18,417,000.On average, 10 Wall Street analysts forecast ALEC's revenue for 2026 to be $2,168,210,877, with the lowest ALEC revenue forecast at $455,203,267, and the highest ALEC revenue forecast at $3,194,194,630. On average, 10 Wall Street analysts forecast ALEC's revenue for 2027 to be $5,852,026,582, with the lowest ALEC revenue forecast at $1,305,656,199, and the highest ALEC revenue forecast at $17,452,049,145.
In 2028, ALEC is forecast to generate $2,137,901,001 in revenue, with the lowest revenue forecast at $455,203,267 and the highest revenue forecast at $3,200,301,015.